By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Wealth Beat NewsWealth Beat News
  • Home
  • News
  • Finance
  • Investing
  • Banks
  • Mortgage
  • Loans
  • Credit Cards
  • Small Business
  • Dept Management
Notification Show More
Aa
Wealth Beat NewsWealth Beat News
Aa
  • News
  • Finance
  • Investing
  • Banks
  • Mortgage
  • Loans
  • Credit Cards
  • Small Business
  • Dept Management
Follow US
Wealth Beat News > News > FBCV ETF: A Value ETF Lacking Of Transparency (BATS:FBCV)
News

FBCV ETF: A Value ETF Lacking Of Transparency (BATS:FBCV)

News
Last updated: 2023/05/25 at 7:39 PM
By News
Share
6 Min Read
SHARE

Contents
FBCV strategy and portfolioPerformanceShortcomings of value fundsTakeaway

This article series aims at evaluating exchange-traded funds (ETFs) regarding the relative past performance of their strategies and metrics of their current portfolios. As holdings change over time, updated reviews are posted from time to time.

FBCV strategy and portfolio

Fidelity Blue Chip Value ETF (BATS:FBCV) is an actively managed ETF launched on 06/02/2020. It has a 12-month distribution yield of 1.39%, a total expense ratio of 0.59% and net assets of $135M. Distributions are paid quarterly. As described in the prospectus by Fidelity, the fund is different from traditional ETFs:

It is not required to publicly disclose its complete portfolio holdings each business day. Instead, the fund publishes each business day on its website a “Tracking Basket,” which is designed to closely track the daily performance of the fund but is not the fund’s actual portfolio.

FBCV invests in companies that are undervalued “in relation to factors such as assets, sales, earnings, growth potential, or cash flow, or in relation to securities of other companies in the same industry.“

The current tracking basket, which is visible on this link, has a weight overlap of 80% with the real portfolio. The portfolio turnover rate was 54% during the most recent fiscal year.

FBCV benchmark is the Russell 1000 Value Index. In this article, it will be compared to the iShares Russell 1000 Value ETF (IWD), and also to the SPDR S&P 500 ETF Trust (SPY). The usual valuation ratios are reported in the next table.

FBCV

IWD

SPY

Price / Earnings TTM

15.26

15.93

21.21

Price / Book

2.1

2.22

3.77

Price / Sales

1.43

1.66

2.4

Price / Cash Flow

10.25

11.41

15.29

Source: Fidelity

FBCV is significantly cheaper than SPY regarding the four ratios, and marginally cheaper than IWD.

Performance

Since inception in June 2020, FBCV has outperformed IWD by 5.2% in total return, and it is shortly behind SPY.

FBCV vs. benchmarks since June 2020

FBCV vs. benchmarks since June 2020 (Seeking Alpha)

The next chart compares FBCV with five other large- and mid-cap value ETFs tracking different indexes:

  • iShares S&P 500 Value ETF (IVE)
  • Vanguard Value Index Fund (VTV)
  • iShares MSCI USA Value Factor ETF (VLUE)
  • First Trust Large Cap Value AlphaDEX Fund (FTA)
  • Invesco Dynamic Large Cap Value ETF (PWV)

FBCV vs. competitors since June 2020

FBCV vs. competitors since June 2020 (Seeking Alpha)

FBCV beats VLUE and, to a lesser extent, PWV. It is very close to IVE, VTV and FTA. However, IVE has been outperforming in the last 12 months:

FBCV vs. competitors, last 12 months

FBCV vs. competitors, last 12 months (Seeking Alpha)

Shortcomings of value funds

Value funds usually rank all stocks on the same criteria. It means the valuation ratios are considered comparable across sectors and industries. Obviously, they are not: my monthly dashboard here shows how valuation and quality metrics may vary across sectors. A consequence is to privilege sectors where valuation ratios are naturally cheaper, especially financials. FBCV prospectus doesn’t tell much about the strategy, but it discloses that companies are compared to their peers in the same industry. The bias across all sectors and industries is likely reduced.

The second weakness of value funds comes from the price/book ratio (P/B), which adds some risk in the strategy. Historical data show that a large group of companies with low P/B has a higher probability to hold value traps than a same-size group with low price/earnings, price/sales or price/free cash flow. Statistically, such a group will also have a higher volatility and deeper drawdowns in price. The next table shows the return and risk metrics of the cheapest quarter of the S&P 500 (i.e. 125 stocks) measured in price/book, price/earnings, price/sales and price/free cash flow. The sets are reconstituted annually between 1/1/2000 and 1/1/2023 with elements in equal weight.

Annual Return

Drawdown

Sharpe ratio

Volatility

Cheapest quarter in P/B

8.54%

-81.55%

0.35

37.06%

Cheapest quarter in P/E

10.71%

-73.62%

0.48

25.01%

Cheapest quarter in P/S

12.82%

-76.16%

0.47

34.83%

Cheapest quarter in P/FCF

15.32%

-74.77%

0.61

27.03%

Data calculated with Portfolio123

This explains why I use P/FCF and not P/B in the Dashboard List model.

FBCV is likely to use similar ratios, including one closely related to P/B. However, it also uses a “growth potential” criterion. It may be the PEG ratio or another metric using EPS growth or sales growth estimates. Anyway, it makes FBCV better than the usual value index ETFs by lowering the risk of picking value traps.

Takeaway

Fidelity Blue Chip Value ETF is an actively managed ETF holding large- and mid-cap stocks with value characteristics. It lacks the transparency of usual ETFs: the strategy and holdings are not disclosed by Fidelity. Moreover, its total assets and average trading volume are quite low. Price history is short: it has beaten its benchmark (represented by IWD), but performance is similar to several competitors. Unlike most value ETFs, it takes into account industry and growth in the stock-picking process.

Read the full article here

News May 25, 2023 May 25, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
Excelerate Energy: Nearby Best Energy-Source Cap-Gain Prospect (NYSE:EE)

The primary focus of this article is Excelerate Energy, Inc. (NYSE:EE). Investment…

Penske Is Steady, But The Road Ahead May Be Bumpy (NYSE:PAG)

Investing Thesis On Wednesday, Penske Automotive Group (NYSE:PAG) released a superficially encouraging…

Top Financial – No, Stop It, This Is Silly (NASDAQ:TOP)

TOP Financial Moves, yes, but why? TOP Financial (NASDAQ:TOP) was quite the…

You Might Also Like

News

Eton Pharmaceuticals Set To Dominate Orphan Drug Niche (NASDAQ:ETON)

By News
News

Wasatch Long/Short Alpha Fund Q1 2025 Commentary

By News
News

Yield Hunting Part 22: Buy Runway Growth’s Baby Bonds, Sell Gladstone’s GLADZ

By News
News

Nufarm Limited (NUFMF) Q2 2025 Earnings Call Transcript

By News
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Contact US
More Info
  • Newsletter
  • Finance
  • Investing
  • Small Business
  • Dept Management

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions

Join Community

2025 © wealthbeatnews.com. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc.

I have read and agree to the terms & conditions
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Lost your password?